Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia.

Baker SJ, Cosenza SC, Ramana Reddy MV, Premkumar Reddy E.

Oncotarget. 2019 Mar 8;10(20):1932-1942. doi: 10.18632/oncotarget.26735. eCollection 2019 Mar 8.

2.

Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia.

Padgaonkar A, Rechkoblit O, Vasquez-Del Carpio R, Pallela V, Venkata Subbaiah D, Cosenza SC, Baker SJ, Ramana Reddy MV, Aggarwal A, Reddy EP.

Oncotarget. 2018 Dec 28;9(102):37753-37765. doi: 10.18632/oncotarget.26514. eCollection 2018 Dec 28.

3.

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.

Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I, Gupta YK, Reddy MV, Ueno L, Hart JR, Vogt PK, Mulholland D, Guha C, Aggarwal AK, Reddy EP.

Cell. 2016 Apr 21;165(3):643-55. doi: 10.1016/j.cell.2016.03.045.

4.

Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).

Reddy MV, Akula B, Jatiani S, Vasquez-Del Carpio R, Billa VK, Mallireddigari MR, Cosenza SC, Venkata Subbaiah DR, Bharathi EV, Pallela VR, Ramkumar P, Jain R, Aggarwal AK, Reddy EP.

Bioorg Med Chem. 2016 Feb 15;24(4):521-44. doi: 10.1016/j.bmc.2015.11.045. Epub 2015 Dec 1.

5.

Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.

Divakar SK, Ramana Reddy MV, Cosenza SC, Baker SJ, Perumal D, Antonelli AC, Brody J, Akula B, Parekh S, Reddy EP.

Leukemia. 2016 Jan;30(1):86-93. doi: 10.1038/leu.2015.185. Epub 2015 Jul 15.

6.

Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140.

Eachkoti R, Reddy MV, Lieu YK, Cosenza SC, Reddy EP.

Eur J Cancer. 2014 Jul;50(11):1982-92. doi: 10.1016/j.ejca.2014.04.017. Epub 2014 May 15.

7.

Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).

Reddy MV, Akula B, Cosenza SC, Athuluridivakar S, Mallireddigari MR, Pallela VR, Billa VK, Subbaiah DR, Bharathi EV, Vasquez-Del Carpio R, Padgaonkar A, Baker SJ, Reddy EP.

J Med Chem. 2014 Feb 13;57(3):578-99. doi: 10.1021/jm401073p. Epub 2014 Jan 24.

8.

Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.

Reddy MV, Mallireddigari MR, Pallela VR, Cosenza SC, Billa VK, Akula B, Subbaiah DR, Bharathi EV, Padgaonkar A, Lv H, Gallo JM, Reddy EP.

J Med Chem. 2013 Jul 11;56(13):5562-86. doi: 10.1021/jm400575x. Epub 2013 Jun 25.

9.

ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathway.

Kang AD, Cosenza SC, Bonagura M, Manair M, Reddy MV, Reddy EP.

PLoS One. 2013;8(3):e58355. doi: 10.1371/journal.pone.0058355. Epub 2013 Mar 7.

10.

Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent.

Pallela VR, Mallireddigari MR, Cosenza SC, Akula B, Subbaiah DR, Reddy EP, Reddy MV.

Org Biomol Chem. 2013 Mar 28;11(12):1964-77. doi: 10.1039/c3ob27220f. Epub 2013 Feb 6.

11.

Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MS.

Cho SY, Cosenza SC, Pallela V, Panda G, Reddy MV, Reddy EP, Roboz J.

J Pharm Biomed Anal. 2013 Mar 5;75:138-44. doi: 10.1016/j.jpba.2012.11.022. Epub 2012 Nov 23.

12.

(Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies.

Reddy MV, Akula B, Cosenza SC, Lee CM, Mallireddigari MR, Pallela VR, Subbaiah DR, Udofa A, Reddy EP.

J Med Chem. 2012 Jun 14;55(11):5174-87. doi: 10.1021/jm300176j. Epub 2012 May 25.

13.

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity.

Reddy MV, Venkatapuram P, Mallireddigari MR, Pallela VR, Cosenza SC, Robell KA, Akula B, Hoffman BS, Reddy EP.

J Med Chem. 2011 Sep 22;54(18):6254-76. doi: 10.1021/jm200570p. Epub 2011 Aug 17.

14.

A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.

Jatiani SS, Cosenza SC, Reddy MV, Ha JH, Baker SJ, Samanta AK, Olnes MJ, Pfannes L, Sloand EM, Arlinghaus RB, Reddy EP.

Genes Cancer. 2010 Apr;1(4):331-45. doi: 10.1177/1947601910371337.

15.

Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase.

Reddy MVR, Pallela VR, Cosenza SC, Mallireddigari MR, Patti R, Bonagura M, Truongcao M, Akula B, Jatiani SS, Reddy EP.

Bioorg Med Chem. 2010 Mar 15;18(6):2317-2326. doi: 10.1016/j.bmc.2010.01.051. Epub 2010 Jan 25.

PMID:
20188579
16.

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.

Chun AW, Cosenza SC, Taft DR, Maniar M.

Cancer Chemother Pharmacol. 2009 Dec;65(1):177-86. doi: 10.1007/s00280-009-1022-9. Epub 2009 May 24.

PMID:
19466411
17.

Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.

Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M.

Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.

18.

Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents.

Reddy MV, Mallireddigari MR, Cosenza SC, Pallela VR, Iqbal NM, Robell KA, Kang AD, Reddy EP.

J Med Chem. 2008 Jan 10;51(1):86-100. Epub 2007 Dec 19.

PMID:
18088089
19.

Differences in binding of (99m)Tc-disintegrins to integrin alphavbeta3 on tumor and vascular cells.

Knight LC, Romano JE, Cosenza SC, Iqbal NM, Marcinkiewicz C.

Nucl Med Biol. 2007 May;34(4):371-81.

20.

Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1.

Reddy NS, Gumireddy K, Mallireddigari MR, Cosenza SC, Venkatapuram P, Bell SC, Reddy EP, Reddy MV.

Bioorg Med Chem. 2005 May 2;13(9):3141-7.

PMID:
15809149
21.

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP.

Cancer Cell. 2005 Mar;7(3):275-86. Erratum in: Cancer Cell. 2005 May;7(5):497. Boomi Nathan, R [corrected to Boominathan, R].

22.

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, Reddy MV, Reddy EP.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1992-7. Epub 2005 Jan 27. Erratum in: Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5635.

23.

Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen.

Song JS, Sainz IM, Cosenza SC, Isordia-Salas I, Bior A, Bradford HN, Guo YL, Pixley RA, Reddy EP, Colman RW.

Blood. 2004 Oct 1;104(7):2065-72. Epub 2004 May 25.

PMID:
15161672
24.
25.
26.

Nuclear oncology and the Imagene concept.

Urbain JL, Vekemans MC, Lemieux SK, Cosenza SC, Senadhi VK, Milestone BN, Reddy EP.

Acta Radiol Suppl. 1997;412:21-8. Review.

PMID:
9240077
27.

Scintigraphic imaging of oncogenes with antisense probes: does it make sense?

Urbain JL, Shore SK, Vekemans MC, Cosenza SC, DeRiel K, Patel GV, Charkes ND, Malmud LS, Reddy EP.

Eur J Nucl Med. 1995 Jun;22(6):499-504.

PMID:
7556292
28.

Induction of c-fos and c-jun mRNA at the M/G1 border is required for cell cycle progression.

Cosenza SC, Yumet G, Soprano DR, Soprano KJ.

J Cell Biochem. 1994 Aug;55(4):503-12.

PMID:
7962180
29.

Cycloheximide protection against actinomycin D cytotoxicity.

Borrelli MJ, Stafford DM, Rausch CM, Ofenstein JP, Cosenza SC, Soprano KJ.

J Cell Physiol. 1992 Dec;153(3):507-17.

PMID:
1280278
30.

Use of antisense oligomers to study the role of c-jun in G1 progression.

Soprano KJ, Cosenza SC, Yumet G, Soprano DR.

Ann N Y Acad Sci. 1992 Oct 28;660:231-9.

PMID:
1340125
31.

Growth-associated gene expression is not constant in cells traversing G-1 after exiting mitosis.

Cosenza SC, Carter R, Pena A, Donigan A, Borrelli M, Soprano DR, Soprano KJ.

J Cell Physiol. 1991 May;147(2):231-41.

PMID:
2040657
32.

A potential role for c-jun in cell cycle progression through late G1 and S.

Carter R, Cosenza SC, Pena A, Lipson K, Soprano DR, Soprano KJ.

Oncogene. 1991 Feb;6(2):229-35.

PMID:
1900357
33.

Tumor cells exhibit deregulation of the cell cycle histone gene promoter factor HiNF-D.

Holthuis J, Owen TA, van Wijnen AJ, Wright KL, Ramsey-Ewing A, Kennedy MB, Carter R, Cosenza SC, Soprano KJ, Lian JB, et al.

Science. 1990 Mar 23;247(4949 Pt 1):1454-7.

PMID:
2321007
35.

Evidence that the time of entry into S is determined by events occurring in early G1.

Cosenza SC, Owen TA, Soprano DR, Soprano KJ.

J Biol Chem. 1988 Sep 5;263(25):12751-8.

36.

Expression of c-myc and induction of DNA synthesis by platelet-poor plasma in human diploid fibroblasts.

Ferrari S, Calabretta B, Battini R, Cosenza SC, Owen TA, Soprano KJ, Baserga R.

Exp Cell Res. 1988 Jan;174(1):25-33.

PMID:
2446899
37.
38.

Normalization of multiple RNA samples using an in vitro-synthesized external standard cRNA.

Toscani A, Soprano DR, Cosenza SC, Owen TA, Soprano KJ.

Anal Biochem. 1987 Sep;165(2):309-19.

PMID:
2447810

Supplemental Content

Loading ...
Support Center